Table 1.
Characteristics of participants at baseline by trial arm
| Variables | AZM (N = 173) | Placebo (N = 174) |
|---|---|---|
| Demographic characteristics, n (%) | ||
| Age categories at baseline | ||
|
<11 years 11–15 years ≥16 years |
25 (14.5) 87 (50.3) 61 (35.3) |
22 (12.6) 73 (42.0) 79 (45.4) |
| Sex | ||
|
Male Female |
93 (53.8) 80 (46.2) |
84 (48.3) 90 (51.7) |
| Country | ||
|
Malawi Zimbabwe |
53 (30.6) 120 (69.4) |
53 (30.5) 121 (69.5) |
| Clinical history | ||
| Viral load (< 1000 copies/ml), n (%) | 100 (58.5) | 94 (54.0) |
| Duration taking ART, median (IQR) | 5.9 (3.8-9.0) | 6.4 (3.9–8.2) |
| Anthropometry, n (%) | ||
| Height for age | ||
|
<-2 ≥-2 |
95 (54.9) 78 (45.1) |
80 (46.0) 94 (54.0) |
| Weight for age | ||
|
<-2 ≥-2 |
98 (56.7) 75 (43.4) |
83 (47.7) 91 (52.3) |
| Spirometry, mean (SD) | ||
| FEV1 | 1.59 (0.50) | 1.71 (0.53) |
| FEV1 z-score | -2.01 (0.76) | -2.0 (0.74) |
| FVC, | 1.89 (0.59) | 2.04 (0.63) |
| FVC z-score | -1.77 (0.97) | -1.71 (0.89) |
| FEV1/FVC | 0.85 (0.08) | 0.84 (0.08) |
| FEV1/FVC z-score | -0.66 (1.14) | -0.74 (1.13) |
| Severity of lung disease, n (%) | ||
| FEV1 z-score | ||
|
<-2 ≥-2 |
78 (45.1) 95(54.9) |
77 (44.3) 97 (55.7) |
| FVC z-score | ||
|
<-2 ≥-2 |
61 (35.9) 109 (64.1) |
54 (32.0) 115 (68.1) |
|
FEV1/FVC z-score <-2 ≥-2 |
18 (10.6) 152 (89.4) |
22 (13.0) 147 (87.0) |
| Resistance to AZM | 15 (8.7) | 20 (11.5) |
AZM: Azithromycin; IQR: Interquartile range; 4 and 2 missing values for FVC and viral load respectively